# Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma

> **NCT02002598** · PHASE1,PHASE2 · TERMINATED · sponsor: **Suzanne Lentzsch, MD** · enrollment: 23 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Bendamustine
- **DRUG:** Carfilzomib
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT02002598
- **Lead sponsor:** Suzanne Lentzsch, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-11
- **Primary completion:** 2019-03-01
- **Final completion:** 2023-07-01
- **Target enrollment:** 23 (ACTUAL)
- **Why stopped:** Slow accrual and loss of funding
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02002598

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02002598, "Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02002598. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*